摘要
本文目的是验证Sumatriptan(英明格Imigran)治疗偏头痛的效果及安全性.采用随机双盲法,共观察105例偏头痛病人.研究结果表明:用Sumatriptan 6mg皮下注射,治疗偏头痛,镇痛效果令人满意.用于治疗一次性头痛,2h完全缓解率(头痛消失)达75%,与文献报道相符.除个别病例用药后有短暂大脑和植物神经功能紊乱症状外,绝大多数病人无不良反应.
This clinical study is to evaluate the efficacy and safety of sumatriptan in patients withacute migraine. Sumatriptan was provided by Glaxo Limited Company. The clinical trial of randomized double - blind placebo controlled study, including 105 patients, was performed by the First Hospital of Beijing Medical University, Beijing Xuan Wu Hospital, and Beijing Friendship Hospital. The results indicatedthat subcutaneous injection of sumatriptan had good effect on patients with acute migraine. This drug produced complete relief of headache in 75. 0% of attacks within 2 hours. Complete relief plus marked improvement of headache accounted for 89. 3% of the attacks. Most of the patients had no adverse events except transient functional disturbances of the cerebrum and autonomic nervous system in a few patients.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1994年第3期143-147,共5页
The Chinese Journal of Clinical Pharmacology
